

# THE USE OF MITOMYCIN C IN OFTHALMIC PATHOLOGIES

Rodríguez-Carrero R<sup>1</sup>., Vergniory, OA<sup>1</sup>., Zapico, I<sup>1</sup>., Puente, P<sup>1</sup>.  
<sup>1</sup>San Agustín Hospital, Pharmacy Department. Avilés. Spain  
rorcarrero@gmail.com



## BACKGROUND

Mitomycin C (MMC) is a drug used in some ofthalmic pathologies. However, this is an off-label use, not approved by the European Medicine Agency (EMA).




## PURPOSE

Analyze the use of MMC in ofthalmic pathologies, describing the pharmacist's activity during the process.


## MATERIAL AND METHOD

Retrospective observational study of patients with ofthalmic pathologies treated with MMC during 2009 and 2010 in a regional hospital. Data was gathered by reviewing clinical histories and the validation of the treatments by the pharmacist.

## RESULTS



neovascular glaucoma  
n=3



### Patologies

dacriorhinocistitis  
n=22


### Pharmacist's activity



- process the authorization for the off-label treatment
- assure the sterile preparation of MMC 0.2mg/ml concentration for intraocular administration

- The treatment consisted in a unique intraocular dose of MMC of 0.2mg.
- Twelve patients (48%) suffered recurrence, 58% of them during the first six months after treatment.

### Treatment outcomes



## CONCLUSIONS

- ✓ Treatment with MMC in these off-label indications was total or partially effective in the majority of the patients, confirming the data in the existing literature.
- ✓ More than half the recurrences took place during the six first months after the administration.
- ✓ The collaboration between the ofthalmology and the pharmacy departments in the development of a protocol for the administration of MMC has speeded up the access of patients to treatment.